Format

Send to

Choose Destination
Clin Infect Dis. 2016 Nov 1;63(9):1202-1204. Epub 2016 Aug 2.

No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.

Author information

1
Johns Hopkins University School of Medicine, Baltimore, Maryland.
2
Kaohsiung Medical University Hospital.
3
National Taiwan University College of Medicine and Hospital, Taipei, Taiwan.
4
Gilead Sciences, Foster City, California.
5
Yonsei University College of Medicine, Seoul, South Korea.
6
New Zealand Liver Transplant Unit, Auckland City Hospital.

Abstract

Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation.

KEYWORDS:

ALT flare; HBV reactivation; HCV/HBV coinfection

PMID:
27486112
DOI:
10.1093/cid/ciw507
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center